[Postprandial lipemia and arteriosclerosis].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to E Windler.
Explore the source record for details and available documents.
The contribution of the low density lipoprotein (LDL) receptor to the removal of chylomicron remnants was determined in vitro and in vivo by using interventions that up- or down-regulate the LDL receptor but not the LDL receptor-related protein (LRP). In vitro, chylomicron remnants and beta-very low density lipoprotein (VLDL) bind to the LDL receptor on endosomal membranes; their binding can be competed by LDL and beta-VLDL and the binding capacity is greatly augmented in membranes from estradiol-treated rats. Likewise, estradiol treatment almost doubled the removal of chylomicron remnants during a single pass through perfused rat livers. However, in vivo the removal of chylomicron remnants and beta-VLDL was very rapid even in untreated rats so that the effect of the stimulation by estradiol was barely detectable when trace amounts of lipoproteins were injected. Yet, when saturating doses of either lipoprotein were injected, the effect of estradiol treatment on the removal of chylomicron remnants and beta-VLDL was readily disclosed. In rats fed a diet containing lard, cholesterol, and bile acids, removal of chylomicron remnants or beta-VLDL was significantly retarded. Likewise, perfused livers from diet-fed rats removed only a mean of 16% of chylomicron remnants during a single passage as compared to 29% in livers from control animals. Also, when large doses of beta-VLDL had been infused into rats for 4 h, in subsequent perfusions of the livers the removal of chylomicron remnants was decreased to 11%. From these results it is concluded that the LDL receptor mediates the hepatic removal of a major fraction of chylomicron remnants and beta-VLDL.
Binding and internalization of chylomicron remnants from rat mesenteric lymph by HepG2 cells was inhibited by both excess remnants and low-density lipoprotein (LDL) to the same extent. Ligand blots revealed binding of remnants and LDL to the LDL receptor. Measures regulating LDL receptor activity greatly influenced the binding of remnants: ethinyloestradiol, the hydroxymethylglutaryl-CoA reductase inhibitor pravastatin and the absence of LDL all increased binding, whereas high cell density or the presence of LDL decreased binding. Also, asialofetuin, asialomucin, the neoglycoprotein galactosyl-albumin and an antibody against the asialoglycoprotein receptor all decreased substantially the binding of remnants. At high cell density, binding internalization and degradation of chylomicron remnants was inhibited by up to 70-80%, yet binding of LDL was inhibited by no more than 20-30%. In cross-competition studies, the binding of 125I-asialofetuin was efficiently competed for by asialofetuin itself or by the antibody, and also by LDL and remnants, yet remnants displayed an approx. 100-fold higher affinity than LDL. Likewise, remnants of human triacylglycerol-rich lipoproteins and asialofetuin interfered with each others' binding to HepG2 cells or human liver membranes. It is concluded that the LDL receptor mediates the internalization of chylomicron remnants into hepatocytes depending on its activity, according to demand for cholesterol. Additionally, the asialoglycoprotein receptor may contribute to the endocytosis of LDL, but predominantly of chylomicron remnants.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The liver supplies peripheral tissues with lipoproteins containing triglycerides, a source of energy, and cholesterol, a structural component of cell membranes. The liver is also capable of taking up lipoproteins and excreting cholesterol in the bile. Because of this unique metabolic role the endocytosis of lipoproteins by the liver was studied. Lipoproteins bind through their component proteins to the low density lipoprotein-receptor of hepatocytes. Apolipoprotein B of low density lipoproteins exhibits fairly low affinity, whereas apolipoprotein E of the postlipolytic remnants of very low density lipoproteins and chylomicrons bind with much higher affinity, which results in a much shorter residence time of these lipoproteins in plasma. Premature uptake is prevented by the C-apolipoproteins, yet. Changes in the phospholipid composition of the lipoproteins during the intraplasmatic lipolysis lead to loss of C-apolipoproteins enabling interaction of apolipoprotein E with the receptors of the liver. Binding is followed by endocytosis into endosomes, which fuse to multivesicular bodies. The contents gets catabolized by hydrolytic enzymes of lysosomes thus becoming available to the cell.
The effect of the new inhibitor of acyl-coenzyme A:cholesterol-acyltransferase, octimibate (sodium 8-[1,4,5-triphenyl-1H-imidazole-2yl)-oxy)octanoate), on the cholesterol transport in rat mesenteric lymph was evaluated. During intraduodenal infusion of a triglyceride-phospholipid emulsion, volume and triglyceride concentration of lymph collected from a mesenteric lymph fistula remained constant in control and treated rats. After addition of 3.75 mg 3H-cholesterol/h to the intraduodenal infusion, cholesterol content of lymph increased to about double the basic concentration in control rats. Yet there was no significant change of lymph cholesterol in treated animals, which had received 40 mg octimibate followed by ca. 120 mg/24 h x kg body weight octimibate added to the intraduodenal infusion. Up to 35% of the infused dose of 3H-cholesterol were recovered in lymph of control rats, in contrast to only 23% in lymph of treated rats. It is concluded that the inhibition of the intestinal acyl-coenzyme A:cholesterol-acyltransferase by octimibate may prevent the increase of cholesterol in mesenteric lymph induced by dietary cholesterol.
Explore the source record for details and available documents.
Lack of volition and immobilizing dizziness were the cardinal presenting symptoms of a 67-year-old man. On account of nonspecific inflammatory signs and weight loss of 18 kg, broad diagnostic tests were undertaken to exclude inflammatory or malignant disease. All were negative, but discrete neurological deficits pointed to cranial nerve or cerebral lesions which had brought about dizziness and dysphagia with vomiting and recurrent aspirations. The cause was found to be a giant aneurysmic dilation and lengthening of the basilar artery. Anticoagulant treatment may be used to reduce the risk of embolism, but complications caused by pressure on cerebral structures or by rupture cannot be avoided.
Explore the source record for details and available documents.